1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim

‘All Stakeholders Responsible’ For Change

 
• By Dean Rudge

Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”

Barrier
Misinformation is one of many barriers to robust and competitive market for biosimilars • Source: Shutterstock

The slow uptake of biosimilars in some markets may stem in part from patients and healthcare providers being subjected at times to “misleading, incomplete, out-of-context, and at times incorrect information about biosimilars,” executives from Sandoz Inc. and Boehringer Ingelheim GmbH argue in an opinion piece for the biologic therapies journal, BioDrugs.

Authored by by Sandoz’s executive director for Scientific Affairs, Hillel Cohen, and edited by Dorothy McCabe, the German firm’s executive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

 
• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

One Month Remains To Enter GGB Awards 2025

 
• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

More from Products

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

 
• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

‘America Leans On Hikma’ And Its $1bn Domestic Drug Manufacturing Investment

 
• By Urtė Fultinavičiūtė

Claiming to be a top-three supplier of sterile injectables in the US, Hikma intends to invest $1bn over the next five years to further expand its American manufacturing base, as the threat of tariffs still looms.

One Month Remains To Enter GGB Awards 2025

 
• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.